patient access – The Milli Chronicle

Thursday, January 8, 2026

Latest:

Trump Expands Oil Strategy with Seizure of Russia-Flagged Tanker Linked to Venezuela
European Allies Coordinate Contingency Plan Amid Renewed US Interest in Greenland
Zelenskiy Seeks Fresh Trump Talks as Ukraine Peace Negotiators Confront Territorial Deadlock
French Budget Talks Resume as Prime Minister Lecornu Navigates a High-Risk Political Balancing Act
India Seeks Airline Fare Data as IndiGo Faces Heightened Antitrust Scrutiny After December Disruptions

Factual Version of a Story

Canadian Pharmacy Platform Expands Affordable Access to Ozempic for US Patients

A Canada-based online pharmacy platform is widening options for American patients by offering India-sourced Ozempic at significantly lower prices, reflecting

Latest Middle East and North Africa News

NewsDesk Milli Chronicle October 9, 2025October 9, 2025 advanced medical treatment, ALS clinical outcomes, ALS drug registration, ALS medication Saudi Arabia, ALS treatment, amyotrophic lateral sclerosis, antisense therapy, clinical trials, Health Sector Transformation Program, innovative therapies, Kingdom healthcare development, nerve cell protection, neurodegenerative disease, neurofilament reduction, orphan drugs, patient access, pharmaceutical innovation, protein misfolding therapy, Qalsody approval, rare disease therapy, rare genetic disease treatment, Saudi Arabia healthcare, Saudi FDA, Saudi medical innovation, Saudi patient care, Saudi rare disease patients, SOD1 gene, SOD1 protein reduction., Tofersen, vision 2030

Saudi FDA Approves Qalsody for ALS, Pioneering New Hope for Rare Disease Patients

Riyadh – In a landmark decision for rare disease treatment in Saudi Arabia, the Saudi Food and Drug Authority (SFDA)